The effectiveness and cost of exogenous pulmonary surfactant replacement therapy

Simple item page
dc.contributor.authorSmith, J.en_ZA
dc.contributor.authorPieper, C.en_ZA
dc.contributor.authorGie, R. P.en_ZA
dc.date.accessioned2011-03-18T14:57:11Z
dc.date.available2011-03-18T14:57:11Z
dc.date.issued1995
dc.descriptionCITATION: Smith, J. Pieper, C. & Gie, R. P. 1995. The effectiveness and cost of exogenous pulmonary surfactant replacement therapy. South African Medical Journal, 85(11):1192-1196.
dc.descriptionThe original publication is available at http://www.samj.org.za
dc.description.abstractThe articles"" recently published on surfactant replacement therapy (SR1) in the treatment of newborn infants with hyaline membrane disease (HMD) being ventilated in a country with limited health resources are both timeous and urgently needed. Surfactant, being an expensive drug, needs to be administered in the most costeffective fashion and for this reason research guidelines for its administration in South Africa are needed. We are concerned that the discussions of this series of articles do not sufficiently emphasise their limitations, as well as the enormous impact of SRT on survival rates and other neonatal morbidities in newborn infants ventilated with HMD.
dc.description.versionPublisher’s version
dc.identifier.issn2078-5135 (online)
dc.identifier.issn0256-9574 (print)
dc.identifier.urihttp://hdl.handle.net/10019.1/7245
dc.language.isoen
dc.publisherHealth & Medical Publishing Group
dc.rights.holderSouth African Medical Journal
dc.subjectNewborn infantsen_ZA
dc.titleThe effectiveness and cost of exogenous pulmonary surfactant replacement therapyen_ZA
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
smith_effectiveness_1995.pdf
Size:
2.3 MB
Format:
Adobe Portable Document Format
Description:
Download article
Download
Collections
Research Articles (Paediatrics and Child Health)